Cargando…

Analysis of Metabolite Distribution in Rat Liver of High-Fat Model by Mass Spectrometry Imaging

Hyperlipidemia is a medical condition characterized by elevated levels of blood lipids, especially triglycerides (TG). However, it remains unclear whether TG levels remain consistently elevated throughout the entire developmental stage of the high-lipid state. In our animal experiment, we found that...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Hongmei, Wang, Wenjun, Xiang, Xuesong, Li, Yan, Zhao, Jinpeng, Huang, Yin, Di, Shuangshuang, Zhuo, Qin, Nie, Honggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057431/
https://www.ncbi.nlm.nih.gov/pubmed/36984851
http://dx.doi.org/10.3390/metabo13030411
_version_ 1785016365511344128
author Mao, Hongmei
Wang, Wenjun
Xiang, Xuesong
Li, Yan
Zhao, Jinpeng
Huang, Yin
Di, Shuangshuang
Zhuo, Qin
Nie, Honggang
author_facet Mao, Hongmei
Wang, Wenjun
Xiang, Xuesong
Li, Yan
Zhao, Jinpeng
Huang, Yin
Di, Shuangshuang
Zhuo, Qin
Nie, Honggang
author_sort Mao, Hongmei
collection PubMed
description Hyperlipidemia is a medical condition characterized by elevated levels of blood lipids, especially triglycerides (TG). However, it remains unclear whether TG levels remain consistently elevated throughout the entire developmental stage of the high-lipid state. In our animal experiment, we found that TG levels were significantly higher in the early stage of the high-lipid model but significantly decreased at the 14th week of the late stage, reaching levels similar to those of the control group. This suggests that TG levels in the high-lipid model are not always higher than those of the control group. To determine the reason for this observation, we used in situ mass spectrometry imaging (MSI) to detect the distribution of metabolites in the liver of rats. The metabolite distribution of the control rats at different stages was significantly different from that of the model rats, and the high-lipid model differed significantly from the control rats. We identified nine functional metabolites that showed differences throughout the period, namely, PA(20:3-OH/i-21:0), PA(20:4-OH/22:6), PG(20:5-OH/i-16:0), PG(22:6-2OH/i-13:0), PG(O-18:0/20:4), PGP(18:3-OH/i-12:0), PGP(PGJ2/i-15:0), SM(d18:0/18:1-2OH), and TG(14:0/14:0/16:0), among which TG was most significantly correlated with hyperlipidemia and high lipid. This study is unique in that it used MSI to reveal the changes in metabolites in situ, showing the distribution of different metabolites or the same metabolite in liver tissue. The findings highlight the importance of considering the animal’s age when using TG as a biomarker for hyperlipidemia. Additionally, the MSI images of the liver in the high-lipid model clearly indicated the distribution and differences of more significant metabolites, providing valuable data for further research into new biomarkers and mechanisms of hyperlipidemia. This new pathway of in situ, visualized, and data-rich metabolomics research provides a more comprehensive understanding of the characteristics of high lipid and its implications for disease prevention and treatment.
format Online
Article
Text
id pubmed-10057431
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100574312023-03-30 Analysis of Metabolite Distribution in Rat Liver of High-Fat Model by Mass Spectrometry Imaging Mao, Hongmei Wang, Wenjun Xiang, Xuesong Li, Yan Zhao, Jinpeng Huang, Yin Di, Shuangshuang Zhuo, Qin Nie, Honggang Metabolites Article Hyperlipidemia is a medical condition characterized by elevated levels of blood lipids, especially triglycerides (TG). However, it remains unclear whether TG levels remain consistently elevated throughout the entire developmental stage of the high-lipid state. In our animal experiment, we found that TG levels were significantly higher in the early stage of the high-lipid model but significantly decreased at the 14th week of the late stage, reaching levels similar to those of the control group. This suggests that TG levels in the high-lipid model are not always higher than those of the control group. To determine the reason for this observation, we used in situ mass spectrometry imaging (MSI) to detect the distribution of metabolites in the liver of rats. The metabolite distribution of the control rats at different stages was significantly different from that of the model rats, and the high-lipid model differed significantly from the control rats. We identified nine functional metabolites that showed differences throughout the period, namely, PA(20:3-OH/i-21:0), PA(20:4-OH/22:6), PG(20:5-OH/i-16:0), PG(22:6-2OH/i-13:0), PG(O-18:0/20:4), PGP(18:3-OH/i-12:0), PGP(PGJ2/i-15:0), SM(d18:0/18:1-2OH), and TG(14:0/14:0/16:0), among which TG was most significantly correlated with hyperlipidemia and high lipid. This study is unique in that it used MSI to reveal the changes in metabolites in situ, showing the distribution of different metabolites or the same metabolite in liver tissue. The findings highlight the importance of considering the animal’s age when using TG as a biomarker for hyperlipidemia. Additionally, the MSI images of the liver in the high-lipid model clearly indicated the distribution and differences of more significant metabolites, providing valuable data for further research into new biomarkers and mechanisms of hyperlipidemia. This new pathway of in situ, visualized, and data-rich metabolomics research provides a more comprehensive understanding of the characteristics of high lipid and its implications for disease prevention and treatment. MDPI 2023-03-10 /pmc/articles/PMC10057431/ /pubmed/36984851 http://dx.doi.org/10.3390/metabo13030411 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mao, Hongmei
Wang, Wenjun
Xiang, Xuesong
Li, Yan
Zhao, Jinpeng
Huang, Yin
Di, Shuangshuang
Zhuo, Qin
Nie, Honggang
Analysis of Metabolite Distribution in Rat Liver of High-Fat Model by Mass Spectrometry Imaging
title Analysis of Metabolite Distribution in Rat Liver of High-Fat Model by Mass Spectrometry Imaging
title_full Analysis of Metabolite Distribution in Rat Liver of High-Fat Model by Mass Spectrometry Imaging
title_fullStr Analysis of Metabolite Distribution in Rat Liver of High-Fat Model by Mass Spectrometry Imaging
title_full_unstemmed Analysis of Metabolite Distribution in Rat Liver of High-Fat Model by Mass Spectrometry Imaging
title_short Analysis of Metabolite Distribution in Rat Liver of High-Fat Model by Mass Spectrometry Imaging
title_sort analysis of metabolite distribution in rat liver of high-fat model by mass spectrometry imaging
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057431/
https://www.ncbi.nlm.nih.gov/pubmed/36984851
http://dx.doi.org/10.3390/metabo13030411
work_keys_str_mv AT maohongmei analysisofmetabolitedistributioninratliverofhighfatmodelbymassspectrometryimaging
AT wangwenjun analysisofmetabolitedistributioninratliverofhighfatmodelbymassspectrometryimaging
AT xiangxuesong analysisofmetabolitedistributioninratliverofhighfatmodelbymassspectrometryimaging
AT liyan analysisofmetabolitedistributioninratliverofhighfatmodelbymassspectrometryimaging
AT zhaojinpeng analysisofmetabolitedistributioninratliverofhighfatmodelbymassspectrometryimaging
AT huangyin analysisofmetabolitedistributioninratliverofhighfatmodelbymassspectrometryimaging
AT dishuangshuang analysisofmetabolitedistributioninratliverofhighfatmodelbymassspectrometryimaging
AT zhuoqin analysisofmetabolitedistributioninratliverofhighfatmodelbymassspectrometryimaging
AT niehonggang analysisofmetabolitedistributioninratliverofhighfatmodelbymassspectrometryimaging